2025年11月8日,火箭制药公司的收入估计数为0.45 EPS,存货为3.17美元。 Rocket Pharmaceuticals beat earnings estimates with $0.45 EPS, stock at $3.17 on Nov. 8, 2025.

火箭制药公司(RCKT)报告,经调整的季度收入为每股0.45美元,击打估计数为0.03美元,比去年的0.71美元损失有所改进。 Rocket Pharmaceuticals (RCKT) reported adjusted quarterly earnings of $0.45 per share, beating estimates by $0.03 and improving from last year’s $0.71 loss. 该股票于2025年11月8日收盘时价格为3.17美元,Wedbush保持了"超强"评级和16.00美元的价格目标,这意味着上率为405%. The stock closed at $3.17 on November 8, 2025, with Wedbush maintaining an “Outperform” rating and a $16.00 price target, implying 405% upside. 该生物技术公司开发稀有疾病的基因疗法,其市场上限为3.42亿美元,低债务,机构所有权为98.39%。 The biotech firm, developing gene therapies for rare diseases, has a market cap of $342 million, low debt, and institutional ownership of 98.39%. 分析师们的意见不一, 均为"持有"评级, 平均目标价格为16.67美元. Analysts are split, with a consensus “Hold” rating and an average price target of $16.67.